Combination therapy for HIV-1 infection-overview: Preclinical and clinical analysis of antiretroviral combinations

Antiviral Research

Volumn 29, Issue 1, 1996, Pages 35-39

  Johnson, Victoria A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Combination therapies; HIV 1; HIV 1 protease inhibitors; RT inhibitors

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0029984359     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00912-4     Document Type: Conference Paper

References (21)

1. Johnson, V.A. (1994) Combination therapy: more effective control of HIV type 1? AIDS Res. Human Retroviruses 10, 907-912.
2. Johnson, V.A., Barlow, M.A., Merrill, D.P., Chou, T.-C. and Hirsch, M.S. (1990) Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. J. Infect. Dis. 161, 1059-1067.
3. Johnson, V.A., Merrill, D.P., Videler, J.A. et al. (1991) Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J. Infect. Dis. 164, 646-655.
4. Richman, D., Rosenthal, A.S., Skoog, M. et al. (1991) BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. Agents Chemother. 35, 305-308.
5. Schinazi, R.F. (1991) Combined chemotherapeutic modalities for viral infections: rationale and clinical potential. In: T.-C. Chou and D.C. Rideout (Eds), Synergism and antagonism in chemotherapy. 1991. Chapter 4, pp. 109-181. Academic Press, Orlando, FL.
6. Johnson, V.A., Merrill, D.P., Chou, T.-C. and Hirsch, M.S. (1992) Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. J. Infect. Dis. 166, 1143-1146.
7. Richman, D.D. (1993) Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37, 1207-1213.
8. Richman, D.D., Meng, T.-C., Spector, S.A., Fischl, M.A., Resnick, L. and Lai, S. (1994) Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J. Acquir. Immune Defic. Synd. 7, 135-138.
9. Caliendo, A.M. and Hirsch, M.S. (1994) Combination therapy for infection due to human immunodeficiency virus type 1. Clin. Infect. Dis. 18, 516-524.
10. Belen'kii, M.S. and Schinazi, R.F. (1994) Multiple drug effect analysis with confidence interval. Antiviral Res. 25, 1-11.
11. Prichard, M.N., Prichard, L.E. and Shipman, C. (1993) Stategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37, 540-545.
12. Ho, D.D., Neumann, A.U., Perelson, A.S. et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 123-126.
13. Wei, X., Ghosh, S.K., Taylor, M.E. et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.
14. Mazzulli, T., Rusconi, S., Merrill, D.P., D'Aquila, R.T., Moonis, M., Chou, T.-C. and Hirsch, M.S. (1994) Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob. Agents Chemother. 38, 656-661.
15. de Jong, M.D., Loewenthal, M., Boucher, C.A. et al. (1994) Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J. Infect. Dis. 169, 1346-1350.
16. St. Clair, M.H., Martin, J.L., Tudor-Williams, G. et al. (1991) Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557-1559.
17. Larder, B.A. (1992) 3′-azido-3′-deoxythymidine resistance suppressed by a mutaiton conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36, 2664-2669.
18. Tisdale, M., Kemp, S.D., Parry, N.R. and Larder, B.A. (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90, 5653-5656.
19. Larder, B.A., Kemp, S.D. and Harrigan, PR. (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269, 696-699.
20. Chow, Y.-K., Hirsch, M.S., Merrill, D.P. et al. (1993) Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361, 650-654.
21. Wakefield, J.K., Jablonski, S.A. and Morrow, C.D. (1992) In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J. Virol. 66, 6806-6812.